One of the major current limitations on wider use of long-acting cabotegravir/rilpivirine injections (CAB/RPV-LA) is the unpredictable risk of virological failure with two-class resistance, despite excellent adherence. This includes concerns about the loss of integrase inhibitors for future ART.
Even though this risk of virological failure in these settings is low, the loss of integrase inhibitors as a class, often also with resistance to NNRTIs, leaves limited choices, largely dependent on PIs.
In a letter to the journal AIDS, Giguère Pierre and colleagues from the University of Ottowa report a case series of five people who responded to bictegravir/emtricitabine/TAF (B/F/TAF), despite developing drug resistance mutations against both cabotegravir and rilpivirine on two-monthly injections.
Read the full news story at HIV i-Base.
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.